Adbry

Tralokinumab is an anti-IL-13 monoclonal antibody approved as Adbry (US) and Adtralza (EU) for moderate-to-severe atopic dermatitis in patients 12 and older [1], with LEO Pharma now pushing into younger pediatric populations (TRAPEDS 1 Phase 2 completed, Phase 3 NCT06311682 recruiting ages 2 to less than 12 plus infants) [2][3] and hand eczema (Phase 3 NCT05958407 / ADHAND, n=235, completed September 2025, results pending) [4][13]. The commercial story is defined by the gap behind dupilumab (Dupixent, Sanofi/Regeneron), which generated more than $13 billion in 2024 across all approved indications [5]. Adbry/Adtralza is now LEO's single largest product, growing 69% CER in 2024 against group revenue of DKK 12,453 million, so pediatric and hand eczema expansion sits squarely on top of LEO's main growth engine [14]. Label expansion for tralokinumab is less about proving the mechanism, which is validated by dupilumab and the 2024 lebrikizumab (Ebglyss) approval, and more about carving incremental share in segments the market leaders already occupy. The two near-term readouts worth tracking are the hand eczema Phase 3 (ADHAND, completed September 2025 per registry) and the pediatric 2-to-11 Phase 3; both will test whether tralokinumab can hold formulary position against Dupixent and Ebglyss.

Tralokinumab is an approved biologic, not a novel compound. FDA cleared it under BLA 761180 on December 27, 2021 as Adbry for moderate-to-severe atopic dermatitis in adults, with pediatric approval for ages 12 and older [1]. LEO Pharma markets the same molecule as Adtralza in Europe. Current pipeline activity centers on label expansion. TRAPEDS 1 (NCT05388760), a Phase 2 pharmacokinetic and safety study in 28 children, completed with trough concentration as the primary endpoint, bridging adult dosing to pediatric use [2]. The main Phase 3 pediatric trial, NCT06311682, is actively enrolling 195 children aged 2 to less than 12 plus a parallel infant cohort, combining tralokinumab with topical corticosteroids [3]. The hand atopic eczema Phase 3 (NCT05958407, ADHAND) completed enrollment of 235 patients and finished its 32-week treatment plus 4-week safety follow-up around September 2025 per the registry, with IGA-AHE 0 or 1 at week 16 as the primary endpoint; a topline readout is the nearest investment catalyst [4][13]. No breakthrough, fast-track, or priority review designations are listed for the pediatric or hand indications. Expected readout dates for the active Phase 3 pediatric program have not been posted in public registries. ECZTRA 6 adolescent 52-week laboratory-parameter data were published in 2026 (Paller et al.) [6]. Tralokinumab composition-of-matter protection is estimated to run to roughly 2028-2029 based on public patent trackers, so biosimilar risk sits on the medium-term horizon rather than the near-term one [15].

IL-13 is a cytokine, a short-lived signaling protein released mostly by Th2 helper T cells, that drives type 2 inflammation [7]. In atopic dermatitis skin, IL-13 is the dominant pathogenic signal: it degrades the skin barrier, triggers itch nerves directly, and recruits eosinophils and mast cells. Patients scratch, scratch breaks the barrier further, more IL-13 floods in, and the cycle repeats. Tralokinumab is a fully human IgG4 antibody that binds IL-13 itself and prevents it from docking at either receptor (IL-13Rα1, which triggers downstream inflammation, and IL-13Rα2, a decoy receptor that soaks up excess cytokine). This differs mechanistically from dupilumab, which blocks the IL-4 receptor alpha subunit shared by IL-4 and IL-13 signaling, shutting both cytokines down upstream. The mechanism is well validated. Dupilumab is approved and dominant, lebrikizumab (another anti-IL-13 antibody) was approved in 2024 as Ebglyss, and genetic variants in IL13 and the IL-4/IL-13 pathway are associated with atopic disease. Open Targets scores IL13 at 0.747 for atopic eczema and 0.70 for asthma [8]. The real question is not whether IL-13 drives AD, but whether blocking IL-13 alone (tralokinumab, lebrikizumab) matches blocking IL-4 and IL-13 together (dupilumab) across efficacy and durability. Real-world 12-month data (Armstrong et al. 2026) suggest tralokinumab holds up on effectiveness and safety outside of trial populations [9].

The pediatric Phase 3 (NCT06311682) is the trial that matters commercially [3]. LEO Pharma is enrolling 195 children aged 2 to less than 12 plus an infant cohort, randomized to tralokinumab with topical corticosteroids versus TCS alone. The primary endpoint is the Investigator's Global Assessment (IGA), a 5-point clinician-rated scale where 0 = clear skin and 4 = severe disease; a score of 0 or 1 at week 16 means the patient's skin looks clear or nearly clear to a trained dermatologist. For context, in the key adult trials ECZTRA 1 and ECZTRA 2, tralokinumab produced week-16 IGA 0/1 rates of roughly 16% and 22% versus 7% and 11% on placebo, so a pediatric response rate in that general range would be read as consistent with the approved adult data; materially better would be a positive surprise, materially worse would raise questions [16]. The TCS-combination design is defensible for ethics and for approvability, but it makes raw effect size harder to read because background steroid use helps the control arm too; Sanofi and Regeneron ran similar TCS-combo designs for pediatric Dupixent and still produced wide separation, so the bar exists. TRAPEDS 1 (NCT05388760) was a 28-patient Phase 2 focused on trough concentration pharmacokinetics, meaning how the drug is absorbed, distributed and cleared in children, now completed [2]. Hand eczema Phase 3 (NCT05958407, ADHAND) completed with 235 patients, primary endpoint IGA-AHE 0 or 1, where IGA-AHE is the Investigator's Global Assessment for Atopic Hand Eczema, a hand-specific version of the same clear/almost-clear clinician rating; the trial finished its 32-week treatment and 4-week safety follow-up around September 2025 and registry results are pending [4][13]. An ophthalmologic adverse-event substudy (NCT05682976, n=100, completed) was run through Nantes University Hospital to characterize the class-effect conjunctivitis signal in real-world AD patients [10]. The adolescent ECZTRA 6 extension (Paller et al., PMID 42033591) reported 52-week lab parameters in 2026 [6].

Tralokinumab is FDA-approved (ADBRY, 2021-12-27). BioCosm's model estimates a drug's first FDA approval, which has already happened here, so no probability is shown - any current trial is a new-indication study.

Efficacy risk is modest but concrete. The pediatric Phase 3 TCS-combo design has helped and hurt comparable readouts; Dupixent's pediatric program produced wide separation, so there is a clear bar. The adult ECZTRA 1/2 week-16 IGA 0/1 placebo-adjusted deltas of roughly 9 to 11 percentage points set the expectation for what a successful pediatric readout should look like [16]. The hand eczema Phase 3 is less certain because IL-13 pathway data in hand eczema is thinner than in whole-body AD, and LEO's own delgocitinib cream (Anzupgo) already competes in that niche. Safety risk centers on conjunctivitis and ocular adverse events, a known class effect of IL-13 blockade. A dedicated ophthalmology study (NCT05682976, n=100, completed) [10] indicates LEO is tracking the signal. Public FAERS queries pulled during writeup drafting suggested on the order of several thousand cumulative reports with roughly one in seven classified serious, dominated by atopic dermatitis flares and injection-site reactions rather than novel toxicity, but these counts are query-methodology-dependent and shift week to week, so they should be treated as directional rather than precise point estimates [11]. Commercial risk is the biggest concern. Dupixent 2024 revenue exceeded $13 billion with pediatric approvals down to 6 months old [5]. Lebrikizumab (Ebglyss, Eli Lilly) launched in 2024 with every-four-week maintenance dosing, versus tralokinumab's every-two-week schedule post-induction; the Armstrong et al. 2026 paper is an indirect comparison (MAIC, matching-adjusted indirect comparison), a statistical technique that reweights patients from one trial to look like those in another to allow a pseudo-comparison across separately conducted trials rather than a true head-to-head randomized study [12]. Adbry needs to demonstrate meaningful incremental value, not non-inferiority, to protect formulary position. Payer coverage for pediatric 2-to-11 use will hinge on whether the data differentiates tralokinumab from Dupixent on efficacy, dosing frequency, or safety. On the medium-term horizon, Adbry composition-of-matter protection is estimated to expire around 2028-2029 per public patent trackers, so biosimilar erosion risk is real but not imminent [15].

Worth watching, with specific signal gates. Two readouts matter: the hand eczema Phase 3 (NCT05958407 / ADHAND, n=235 completed around September 2025, results pending) [4][13] and the main pediatric Phase 3 (NCT06311682, ages 2 to less than 12, recruiting) [3]. Hand eczema matters because it is an unmet-need subpopulation where delgocitinib and dupilumab have both staked claims; a positive IGA-AHE 0/1 separation of 15 points or more over placebo would open a defensible niche. The pediatric 2-to-11 readout determines whether Adbry can compete head to head with Dupixent in a segment where Sanofi and Regeneron have a multi-year head start. LEO Pharma is privately held, so there is no earnings call, but LEO publishes annual and interim reports at leo-pharma.com/our-annual-reporting; the 2024 report shows Adbry/Adtralza as LEO's largest product with 69% CER growth and group revenue of DKK 12,453 million, though LEO does not break out exact Adbry-only revenue in its public summaries [14]. Signal that would shift the thesis up: pediatric efficacy that reads at least as strong as the adolescent 16-week numbers in ECZTRA 6, with a conjunctivitis rate at or below adult levels. Signal that would shift it down: hand eczema missing on primary endpoint or pediatric safety flagging ocular events. Check back when NCT05958407 posts registry results and when NCT06311682 updates its primary completion date. An audit note: this node is tagged pipeline but the molecule is approved; a reclassification to drug with pediatric-expansion sub-trials would better match the dataset's structure for similar approved-with-pediatric-trial compounds.